Lung Cancer Clinical Trial

Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer

Summary

This study is determining the maximum tolerated dose and safety of SU011248 (sunitinib malate, SUTENT) in combination with docetaxel (Taxotere). Several dosing regimens will be tested in patients with advanced solid tumors, including non small cell lung cancer.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Advanced solid tumor malignancy ECOG 0 or 1

Exclusion Criteria:

Prior treatment with with high-dose chemotherapy requiring stem cell rescue Prior irradiation to ≥25% of the bone marrow (e.g. whole pelvis=25%) Patients with centrally located lung lesions unless recently treated with radiotherapy

Study is for people with:

Lung Cancer

Phase:

Phase 1

Estimated Enrollment:

49

Study ID:

NCT00712504

Recruitment Status:

Completed

Sponsor:

Pfizer

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 4 Locations for this study

See Locations Near You

Pfizer Investigational Site
Birmingham Alabama, 35233, United States
Pfizer Investigational Site
Birmingham Alabama, 35233, United States
Pfizer Investigational Site
Birmingham Alabama, 35294, United States
Pfizer Investigational Site
Nashville Tennessee, 37232, United States
Pfizer Investigational Site
Madison Wisconsin, 53792, United States

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 1

Estimated Enrollment:

49

Study ID:

NCT00712504

Recruitment Status:

Completed

Sponsor:


Pfizer

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider